Scarica l'app Stockscreener
10.85
4.24%
-0.48
Dopo l'orario di chiusura:
10.85
Arvinas Inc Borsa (ARVN) Ultime notizie
How The Arvinas (ARVN) Story Is Evolving As 2026 Neurology Catalysts Approach - Yahoo Finance
ARVN Technical Analysis & Stock Price Forecast - Intellectia AI
Arvinas, Inc. (ARVN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arvinas (NASDAQ:ARVN) Shares Down 5.1%Time to Sell? - marketbeat.com
Arvinas Shares Surge 6.9% on Positive Pipeline Expectations - Intellectia AI
Arvinas (ARVN) Rises 6.9%: Can This Momentum Be Sustained? - Bitget
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last? - Yahoo Finance
Pullback Watch: Can Arvinas Inc ride the EV waveMarket Trend Report & High Accuracy Trade Alerts - baoquankhu1.vn
Arvinas (ARVN) price target increased by 13.60% to 15.54 - MSN
Aug Summary: How does Arvinas Inc correlate with Nasdaq2026 Key Highlights & Accurate Intraday Trade Tips - baoquankhu1.vn
ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Vanguard realignment leaves Arvinas (ARVN) ownership listed as 0 shares - Stock Titan
Arvinas patents new PROTACs for the degradation of BCL-6 - bioworld.com
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Hold" from Analysts - marketbeat.com
Aug EndMonth: Is Arvinas Inc in a bullish channelMarket Growth Review & Weekly Breakout Watchlists - baoquankhu1.vn
ARVN PE Ratio & Valuation, Is ARVN Overvalued - Intellectia AI
H.C. Wainwright reiterates Arvinas stock rating on trial data - Investing.com UK
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gossamer Bio (GOSS), High Tide (HITI) and Arvinas Holding Company (ARVN) - The Globe and Mail
H.C. Wainwright reiterates Arvinas stock rating on trial data By Investing.com - Investing.com Australia
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), HOYA (OtherHOCPF) and TransMedics Group (TMDX) - The Globe and Mail
Arvinas’ chief medical officer Berkowitz sells $71k in shares By Investing.com - Investing.com Australia
Noah Berkowitz Sells 6,435 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Arvinas’ chief medical officer Berkowitz sells $71k in shares - Investing.com UK
Arvinas (ARVN) CMO reports automatic RSU tax-withholding share sale - Stock Titan
Tranche Update on Arvinas, Inc.'s Equity Buyback Plan announced on September 17, 2025. - MarketScreener
Arvinas (ARVN): Citigroup Raises Price Target to $21.00 and Main - GuruFocus
Arvinas (NASDAQ:ARVN) Price Target Raised to $21.00 at Citigroup - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Arvinas (NASDAQ:ARVN) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
BTIG Analyst Raises Price Target for Arvinas (ARVN) to $16 | ARV - GuruFocus
Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Arvinas reports positive Phase 1 data for Parkinson’s drug ARV-102 By Investing.com - Investing.com South Africa
Arvinas reports positive Phase 1 data for Parkinson’s drug ARV-102 - Investing.com India
BTIG raises Arvinas stock price target on positive trial data By Investing.com - Investing.com Australia
Arvinas, Inc. (ARVN) reports Q4 loss, misses revenue estimates - MSN
BTIG raises Arvinas stock price target on positive trial data - Investing.com
ARV-102 Data Strengthens Neurodegeneration Pipeline Prospects, Supporting Higher $16 Target and Buy Rating on Arvinas - TipRanks
Arvinas (ARVN) Reports Promising Phase 1 Trial Results for ARV-102 in Parkinson's Disease - GuruFocus
Truist reiterates Hold on Arvinas stock after Parkinson’s trial data By Investing.com - Investing.com Australia
Arvinas, Inc. Reports Forward-Looking Statements and Updates on ARV-102 Neurodegenerative Disease Program – March 2026 - Minichart
Truist reiterates Hold on Arvinas stock after Parkinson’s trial data - Investing.com
Arvinas (NASDAQ:ARVN) Trading Down 7.8%What's Next? - MarketBeat
Arvinas Reports Positive Phase 1 Data for ARV-102 - TipRanks
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days - The Manila Times
Arvinas (ARVN) reports positive Phase 1 ARV-102 data in Parkinson’s disease - Stock Titan
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing - GlobeNewswire
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days - Bitget
Arvinas shows market leadership with jump to 92 RS rating - MSN
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):